Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
The Opioid Risk Tool (ORT) is a brief risk-screening instrument used to estimate potential opioid misuse risk in chronic pain treatment contexts. It incorporates family/personal substance history, age range, trauma history, and psychological comorbidity profile.
Formula: ORT total is the sum of weighted risk factors, with common risk bands: 0-3 low, 4-7 moderate, >=8 high.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
The ORT assigns different point values to each risk item depending on the patient's sex, reflecting different epidemiological patterns of substance use and trauma history. The five items and their gender-specific weights are: (1) Family history of substance abuse — alcohol (M=3, F=1), illegal drugs (M=3, F=2), prescription drugs (M=4, F=4); (2) Personal history of substance abuse — alcohol (M=3, F=1), illegal drugs (M=4, F=5), prescription drugs (M=4, F=4); (3) Age 16-45 (M=1, F=1); (4) History of preadolescent sexual abuse (M=0, F=3); (5) Psychological disease — ADHD, OCD, bipolar, schizophrenia (M=2, F=2), depression (M=1, F=1). Use the gender-specific weights precisely — using male weights for female patients or vice versa is a scoring error.
After assigning gender-specific weights to each applicable risk factor, sum all points to produce a total score. The maximum possible score is 26 for males and 26 for females (different items reach maximum differently). Each risk factor should be verified through clinical history — ask specifically about family and personal substance use history, age, trauma history, and psychiatric diagnoses. The ORT should be administered and documented before initiating long-term opioid therapy.
Low risk (0-3): 3.1% predicted aberrant drug behavior — standard monitoring (periodic urine drug screening, PDMP check, annual reassessment). Moderate risk (4-7): 28.1% predicted aberrant behavior — enhanced monitoring (more frequent UDS, smaller prescription quantities, more frequent visits). High risk (8 and above): 91.9% predicted aberrant behavior — intensive monitoring (frequent UDS, very small supplies, monthly visits, risk counseling, consider pain specialist co-management). High ORT does NOT preclude opioid therapy — it mandates proportionately intensive monitoring and risk mitigation.
Pain Medicine Specialists
Pain medicine practices use the ORT as a standard pre-opioid assessment tool to classify risk stratification and determine monitoring intensity. The ORT score directly informs the monitoring plan documented in opioid treatment agreements and clinical records.
General Practitioners
Primary care physicians use the ORT to structure opioid initiation conversations, identify high-risk patients requiring specialist co-management, and document clinical reasoning for prescribing decisions in the context of state PDMP requirements and regulatory oversight.
Primary Care Providers
The ORT provides a structured framework for discussing individual addiction risk factors with patients before starting opioids. Transparent discussion of risk scores builds therapeutic alliance and helps patients participate in designing appropriate monitoring plans.
Prescribers
All US states have prescription drug monitoring programs (PDMPs) requiring prescriber checks before controlled substance prescribing. ORT documentation supports the clinical reasoning required for PDMP registration and demonstrates appropriate risk assessment in regulatory reviews.
Pain Specialists
For patients already on long-term opioid therapy, the ORT reassessment identifies those who have developed new risk factors or whose risk profile warrants escalation of monitoring intensity including urine drug screening frequency and prescription supply limitations.
The ORT is a pre-opioid initiation tool. Its clinical value is in informing the monitoring plan and risk-benefit discussion before the first prescription, not after aberrant behaviors have already occurred. The CDC 2022 Clinical Practice Guideline for Prescribing Opioids explicitly recommends risk assessment using validated tools like the ORT before initiating long-term opioid therapy for chronic pain.
The ORT was designed to stratify risk and guide monitoring intensity, not to provide binary prescribing decisions. Denying opioid therapy to high-ORT patients in uncontrolled pain is not the appropriate clinical response. Rather, high ORT (8+) signals the need for more frequent clinic visits, smaller prescription supplies, routine urine drug screening, PDMP checks, and possibly pain specialist co-management. Risk stratification enables individualized, proportionate monitoring.
The ORT's most important technical feature is that item weights differ by patient sex. The preadolescent sexual abuse item scores 0 for males and 3 for females. Personal history of illegal drug abuse scores 4 for males but 5 for females. Family history of alcohol abuse scores 3 for males but 1 for females. These gender differences reflect real epidemiological patterns and substantially affect total scores. Always verify the patient's sex before applying weights — using the wrong column is a significant scoring error.
All 50 US states have prescription drug monitoring programs (PDMPs) that track controlled substance prescriptions. Before prescribing opioids, checking the state PDMP to identify multiple-prescriber patterns, early refills, and concurrent controlled substance prescriptions from other providers is mandatory in most states. The ORT complements PDMP checking by adding historical risk factor information that the PDMP alone does not capture (family history, trauma history, psychiatric comorbidity).
Urine drug screening (UDS) is recommended at baseline before starting opioid therapy and at periodic intervals during treatment (quarterly to annually depending on risk level) for all patients on long-term opioid therapy. UDS results should be interpreted in clinical context — unexpected findings warrant discussion with the patient, not automatic discharge. Low ORT patients may need annual UDS; high ORT patients may need monthly UDS. Document UDS results and clinical interpretation in the medical record.
Naloxone (Narcan) co-prescription is recommended by CDC and VA/DoD guidelines for all patients on opioids above 50 morphine milligram equivalents (MME) per day, all patients with high ORT scores, patients with any substance use history, and patients who combine opioids with benzodiazepines or sedative-hypnotics. Naloxone availability at home allows family members to reverse accidental or intentional overdose. Most state PDMPs now facilitate naloxone prescribing documentation.
Opioid treatment agreements (patient-provider agreements or 'pain contracts') document the expectations, risks, monitoring requirements, and consequences of opioid therapy. Many pain medicine and primary care guidelines recommend them as part of opioid prescribing. However, the evidence that they reduce aberrant drug behavior or improve outcomes is mixed, and they should be viewed as part of a comprehensive monitoring strategy rather than a standalone intervention. They do serve an important documentation and shared-decision-making function.
The ORT was developed and validated in a specialty pain clinic population where patients were being evaluated for opioid therapy. Multiple subsequent validation studies in primary care settings have shown lower predictive validity (lower AUC) in primary care populations. This reflects differences in patient population, prescribing context, and the base rate of aberrant drug behaviors. In primary care settings, the ORT should be used as one component of risk assessment alongside PDMP checking, UDS, and clinical judgment rather than as a definitive risk calculator.
ORT published by Webster and Webster (Pain Med 2005) from 185 chronic pain patients. High risk (8+): 91.9% aberrant drug behavior; low risk (0-3): 3.1%. Internal consistency alpha 0.86. Multiple validation studies in specialty pain populations; variable performance in primary care settings. CDC Opioid Prescribing Guidelines (2022) recommend risk assessment tools before initiating opioids. VA/DoD Clinical Practice Guideline for Opioid Therapy (2022) recommends ORT as one of multiple risk assessment tools. PDMPs mandate by state health departments (all US states now have PDMPs).
Higher ORT scores indicate higher potential opioid misuse risk and support stronger safety planning and follow-up.
Use during chronic pain assessment when opioid therapy is being considered or reviewed.
ORT is a screening aid and does not diagnose substance use disorder; predictive performance varies by population and setting.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Quick four-question alcohol screening using the CAGE questionnaire. A score of 2 or more suggests possible alcohol problems. For comprehensive screening, use [AUDIT](/tools/audit).
OpenMental HealthScreen for hazardous and harmful alcohol use with the 10-question AUDIT. Scores range from 0 to 40 across four risk zones. For quick screening use [CAGE](/tools/cage).
OpenMental HealthFree PHQ-9 depression screening questionnaire. Take the Patient Health Questionnaire-9 to assess depression severity with instant scoring and interpretation. Also screen for anxiety with [GAD-7](/tools/gad7).
OpenMental HealthFree GAD-7 anxiety screening questionnaire. Take the Generalized Anxiety Disorder 7-item scale to assess anxiety severity with instant scoring and interpretation. Also screen for depression with [PHQ-9](/tools/phq9).
Open